Gilead, Jazz Among 4 Top Big Cap Medicals To Watch

By | August 27, 2014

Scalper1 News

Today’s Screen of the Day features four institutional-quality drug and medical Big Caps stocks with solid fundamentals. Jazz Pharmaceuticals (JAZZ), which has a market cap of $9.85 billion, earned an IBD Composite Rating of 99, which means that it has outperformed 99% of all stocks in key metrics such as earnings and sales. Best-selling narcolepsy medication Xyrem made up two-thirds of Jazz’s second-quarter sales. The company acquired Italian Scalper1 News

Scalper1 News